Skip to content
Canadian orders above $200 ship free · Dispatched from Canadian stock

Buy Tesamorelin in Canada

Tesamorelin in Canada

Tesamorelin as lyophilised powder, offered in 5 mg and 10 mg vials. Every batch is HPLC tested and dispatched from Canadian stock. For laboratory research use only.

Format
Size
$61.50$12.30/mg
Dispatched from Canadian stock

Buy more, pay less per vial

Add 2 more to save 4%

Frequently bought together

At a glance
Also known as
Tesamorelin acetate · Egrifta · stabilised GHRH(1-44)
Class
Growth hormone-releasing hormone (GHRH) analogue
Form
Lyophilised powder, as 5 mg and 10 mg vials
Sizes
5 mg · 10 mg
Storage, dry
−20 °C, dry and dark
Storage, mixed
2–8 °C, use within 28 days of mixing (as generally reported for reconstituted peptides)
BAC water per size
5 mg: 2 mL · 10 mg: 2 mL

What is Tesamorelin?

Tesamorelin is a growth hormone-releasing hormone (GHRH) analogue. The work published on it is in human. Several names across the literature all denote the same material, among them Tesamorelin acetate, Egrifta and stabilised GHRH(1-44). Its sequence is recorded as 44 amino acids, based on human GHRH(1-44), with a stabilising modification.. All 8 of the 8 studies set out below are controlled trials in people. In the literature it turns up as Tesamorelin acetate, Egrifta and stabilised GHRH(1-44). We keep it here as lyophilised powder in 5 mg and 10 mg vials, for laboratory work only. It is neither a medicine nor meant for use in humans or animals.

What the research shows

StudyModelDose usedDurationFinding
Falutz J et al.2010 · J Acquir Immune Defic Syndr · PMID 20101189Human, randomised, double-blind, placebo-controlled trial with a safety extension, people with HIV and excess abdominal fat (n=404)2 mg s.c. once daily6 months, then a 6-month rerandomised extensionVisceral fat fell by 10.9% with tesamorelin vs 0.6% with placebo over 6 months (P < 0.0001), and by about 18% in those continuing for 12 months. IGF-I rose with no change in glucose parameters; the gains were rapidly lost in those switched to placebo.
Falutz J et al.2008 · AIDS · PMID 18690162Human, randomised, placebo-controlled trial and extension, people with HIV and central fat accumulation (n=410)2 mg s.c. once daily26 weeks, then a 26-week extension (52 weeks total)The drop in visceral fat was sustained at 18% over 52 weeks, with triglycerides down 51 mg/dl (both P < 0.001 vs baseline). Adverse events were comparable between phases and glucose changes were not clinically significant; visceral fat reaccumulated after stopping.
Stanley TL et al.2014 · JAMA · PMID 25038357Human, randomised, double-blind, placebo-controlled trial, people with HIV and abdominal fat accumulation (n=50)2 mg s.c. once daily6 monthsVisceral fat changed by −34 cm² with tesamorelin vs +8 cm² with placebo (P = .005), and liver fat fell by a median 2.0% vs a rise of 0.9% (P = .003). Fasting glucose rose at 2 weeks, but glucose changes over 6 months were not significant.
Stanley TL et al.2019 · Lancet HIV · PMID 31611038Human, randomised, double-blind, multicentre trial, people with HIV and non-alcoholic fatty liver disease (n=61)2 mg once daily12 months, then a 6-month open-label phaseHepatic fat fraction fell by an absolute 4.1% more than with placebo (p = 0.018), a 37% relative reduction. After 12 months 35% on tesamorelin and 4% on placebo had a fat fraction under 5%; fasting glucose and HbA1c did not differ between groups.
Clemmons DR et al.2017 · PLoS One · PMID 28617838Human, randomised, placebo-controlled trial, patients with type 2 diabetes (n=53)1 or 2 mg12 weeksThere were no significant differences between groups in relative insulin response, fasting glucose, HbA1c or overall diabetes control. Total and non-HDL cholesterol fell significantly in the 2 mg group.
Makimura H et al.2014 · J Clin Endocrinol Metab · PMID 24178787Human, randomised, double-blind, placebo-controlled trial, obese adults with reduced GH secretion (n=39)Not stated in the abstract12 monthsIGF-I rose by 102.9 μg/L with tesamorelin vs 22.8 μg/L with placebo (P = .02). Increases in IGF-I correlated with faster phosphocreatine recovery after exercise, a marker the authors link to mitochondrial function.
Adrian S et al.2019 · J Frailty Aging · PMID 31237318Human, secondary analysis of two randomised trials, people with HIV and abdominal obesity (193 tesamorelin responders, 148 placebo)Not stated in the abstract26 weeksAmong responders, tesamorelin was associated with significantly greater increases in the density of four trunk muscle groups and in lean muscle area (all p < 0.005) compared with placebo.
Ellis RJ et al.2025 · J Infect Dis · PMID 39813152Human, randomised, open-label phase 2 trial vs standard of care, people with HIV, abdominal obesity and neurocognitive impairment (n=73)2 mg s.c. daily6 monthsWaist circumference fell more with tesamorelin (median difference −2.7 cm; P = .015), but the change in neurocognitive performance did not differ between groups (P = .673).

What these studies don't show: There are trials, but they cover less ground than they might appear to. The people enrolled are a selected group, the endpoints tend to be surrogate markers in place of hard outcomes, and the follow-up is seldom long. None of that settles safety beyond the specific conditions of each trial. Purity data verifies what sits in the vial and says nothing about whether a compound has any effect.

Every study links to its PubMed record. See all Tesamorelin studies in the research library →

Tesamorelin price in Canada: 5mg and 10mg vials

Buy Tesamorelin in Canada in 2 vial sizes and a starter kit. Prices are in Canadian dollars, you pay by Interac e-Transfer or bank transfer, and orders are shipped from Canadian stock.

SizePricePer mg
5 mg$61.50$12.30/mg
10 mg$85.50$8.55/mg

Starter kit

Is Tesamorelin available in Canada?

Tesamorelin is authorized as a prescription medicine in Canada. Health Canada keeps that database open, so the status can be verified rather than taken on trust. Its Canadian authorization is as EGRIFTA (Theratechnologies), DIN 02438712. That authorization applies to the licensed product rather than research material, and Borealis Peptides provides this for laboratory work only. How Health Canada treats research peptides →

Side effects reported in studies

Every statement here is linked to the study that reported it. Tolerability observations from the cited papers are given below in the authors own terms. Human work on this scale does not pin down a safety profile.

Tesamorelin FAQ

What is Tesamorelin?

In the literature Tesamorelin is characterised as a growth hormone-releasing hormone (GHRH) analogue. Its published work is in human. Borealis Peptides provides it as lyophilised powder in 5 mg and 10 mg vials for in-vitro laboratory research. It holds no authorization as a medicine and is not for use in any living subject. Each study on this page carries its model and the outcome its authors recorded.

Where can I buy Tesamorelin in Canada?

Straight from Borealis Peptides, kept in Canadian stock so nothing crosses a border to reach you. Available in 5 mg and 10 mg vials. Purity is verified by HPLC one batch at a time, and we supply for laboratory research only.

Is Tesamorelin legal in Canada?

Tesamorelin is authorized as a prescription medicine in Canada. Its Canadian authorization is as EGRIFTA (Theratechnologies), DIN 02438712. That authorization applies to the licensed product rather than research material, and Borealis Peptides provides this for laboratory work only. Because Health Canada has stated that "Research Use Only" labelling does not make a product legal to use in a person, we understand it as a note on what the material is for, never an authorisation. Establishing lawful use in your own setting is down to you.

How much Tesamorelin should I use?

Borealis Peptides offers no dosing, protocols or reconstitution volumes and will not supply them even when asked. In the lab the quantity is dictated by the study design, something a supplier is in no position to set. The numbers on this page are simply what particular published studies used within their own models: a record of what was done, not a recommendation.

What human evidence is there for Tesamorelin?

Of the 8 studies cited, 8 are controlled trials in people, with the remainder being animal or cell work. Every row states its model, the amount used and the authors' reported finding, so each study's weight can be assessed first-hand instead of through a summary.

How long does Tesamorelin keep?

Keep sealed vials at −20 °C, dry and dark. Once in solution, store at 2–8 °C. The lyophilised powder withstands ambient temperature in transit, so it ships without ice and goes into the fridge on arrival. The real risks are repeated freeze-thaw cycles and light exposure, not the shipping itself.

How is the purity of Tesamorelin confirmed?

Each batch is HPLC tested before sale, and the certificate refers to the batch in your vial rather than to the product as a whole. Filing that batch number with your records is what lets an observation be reproduced later. Certificates are available on request.

How does Tesamorelin compare with Ipamorelin and CJC-1295 (no DAC)?

They are distinct compounds with distinct published records, and this site does not rank them. Ipamorelin and CJC-1295 (no DAC) have 8 cited studies and 6 cited studies on their page against 8 here. Place the two evidence tables side by side and the difference shows directly.

Compare with